The following is excerpted from the question-and-answer section of the transcript.
(Questions from industry analysts are provided in full, but answers are omitted - download the transcript to see the full question-and-answer session)
Question: Scott Henry - Roth Capital Partners - Analyst
: Thank you, and good afternoon. Cash flow positive in the first quarter of 2024 would be fantastic -- so if you can achieve that goal. So I just wanted
to drill a little bit into the assumptions. I know you expect flattish revenues in the first half of this year, but what sort of revenue run rate do you
think would allow you to achieve that goal?
REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us
consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies.
JUNE 08, 2023 / 9:00PM, VVOS.OQ - Q1 2023 Vivos Therapeutics Inc Earnings Call
Question: Scott Henry - Roth Capital Partners - Analyst
: Okay. Thank you. That's helpful. And when I look at the expense items, obviously sales and marketing was way down. And I know there was layoffs
recently. I want to hone in -- firstly, is that sales and marketing level of $600,000 -- is that what we should think about going forward?
And second of all, that G&A of $6.5 million, I imagine that's where the bulk of the cuts are going to come to. What should we think about as G&A
once all the cuts and everything has taken effect?
Question: Scott Henry - Roth Capital Partners - Analyst
: Okay. Thank you. That's helpful. Just a couple other small questions. Arches were down in the quarter. And if you calculate arches per doc, they
were down -- significantly. How should we think about that number? I mean, I know the business model is always changing and the accounting is
changing as well. Just trying to get a sense of how we should think about that number as far as arches -- how we should interpret the first quarter
2023 results and how we should think about that number going forward?
Question: Scott Henry - Roth Capital Partners - Analyst
: Okay, great. Thank you. Final question, Kirk. Brad set a pretty high bar for you, getting to $8 million a quarter. How do you expect -- what are the
levers you're going to pull to get there from here? How much do you get from the AFD acquisition -- is it the DMEs? Just in big picture terms, what
are the levers you got to pull to get from here to there? Thank you.
Question: Scott Henry - Roth Capital Partners - Analyst
: Okay, great. Thank you for taking the questions.
Question: Lucas Ward - Ascendiant Capital Markets - Analyst
: Thank you. Hi, guys, and congratulations on meeting your business goals and getting closer to your two-year goals. I'm also interested in the
revenue aspect. I was wondering if you could quantify the impact of sales through the DME and the DSO channel -- like near term or in a few
quarters. Just so we can understand how big that really is.
REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us
consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies.
JUNE 08, 2023 / 9:00PM, VVOS.OQ - Q1 2023 Vivos Therapeutics Inc Earnings Call
Question: Lucas Ward - Ascendiant Capital Markets - Analyst
: Okay, thanks, Kirk. One more question. You guys have mentioned that the AFD acquisition fills out an important product gap for you guys in terms
of having more economical solutions for providers. Could you give us an update on the sales traction of the AFD devices?
REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us
consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies.
JUNE 08, 2023 / 9:00PM, VVOS.OQ - Q1 2023 Vivos Therapeutics Inc Earnings Call
Question: Lucas Ward - Ascendiant Capital Markets - Analyst
: Okay, great. Thank you very much.
| 
